Navamedic ASA is a Nordic pharmaceutical company established in 2002, with headquarters in Oslo. The company specializes in products within consumer health and medical nutrition, with a particular focus on rare metabolic diseases. With a portfolio comprising 84 products, Navamedic has also launched Eroxon®, a clinically proven treatment for erectile dysfunction.
The company is engaged in sustainable initiatives and community support, and offers partnerships within in-licensing and out-licensing as well as joint ventures. Navamedic has products available in 13 countries, which underlines their presence in the international market. The company is recognized as a reliable, high-quality supplier in its field.
